MEP90508A - New pharmaceutical composition - Google Patents

New pharmaceutical composition

Info

Publication number: MEP90508A
Authority: ME; Montenegro
Prior art keywords: pharmaceutical composition; new pharmaceutical; relates; present; composition
Prior art date: 2000-07-28

Application number

MEP-905/08A

Other languages

English (en)

Croatian (hr)

Inventor

Pierre Barbier

Paul Hadvary

Hans Lengsfeld

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-28

Filing date

2001-07-19

Publication date

2011-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169384&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP90508(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-07-19 Application filed filed Critical

2011-12-20 Publication of ME00671B publication Critical patent/ME00671B/me

2011-12-20 Publication of MEP90508A publication Critical patent/MEP90508A/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
239000000203 mixture Substances 0.000 abstract 2
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
229940086609 Lipase inhibitor Drugs 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
239000003613 bile acid Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 1
229960001243 orlistat Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Virology (AREA)
Diabetes (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Child & Adolescent Psychology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

MEP-905/08A 2000-07-28 2001-07-19 New pharmaceutical composition MEP90508A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00116393		2000-07-28
PCT/EP2001/008363 WO2002009815A2 (en)	2000-07-28	2001-07-19	New pharmaceutical composition

Publications (2)

Publication Number	Publication Date
ME00671B ME00671B (me)	2011-12-20
MEP90508A true MEP90508A (en)	2011-12-20

Family

ID=8169384

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-905/08A MEP90508A (en)	2000-07-28	2001-07-19	New pharmaceutical composition

Country Status (37)

Country	Link
US (5)	US6756364B2 (es)
EP (1)	EP1307264B1 (es)
JP (2)	JP4265911B2 (es)
KR (1)	KR100572785B1 (es)
CN (1)	CN100423715C (es)
AR (1)	AR033548A1 (es)
AT (1)	ATE279961T1 (es)
AU (2)	AU2001289699B2 (es)
BR (1)	BR0112799B1 (es)
CA (1)	CA2416901C (es)
CZ (1)	CZ302087B6 (es)
DE (1)	DE60106623T2 (es)
EC (1)	ECSP034450A (es)
EG (1)	EG24357A (es)
ES (1)	ES2230362T3 (es)
GT (1)	GT200100152A (es)
HR (1)	HRP20030029B1 (es)
HU (1)	HU229292B1 (es)
IL (2)	IL154008A0 (es)
JO (1)	JO2320B1 (es)
MA (1)	MA26937A1 (es)
ME (1)	MEP90508A (es)
MX (1)	MXPA03000771A (es)
MY (1)	MY127247A (es)
NO (1)	NO330546B1 (es)
NZ (1)	NZ523684A (es)
PA (1)	PA8523201A1 (es)
PE (1)	PE20020336A1 (es)
PL (1)	PL204443B1 (es)
PT (1)	PT1307264E (es)
RS (1)	RS50397B (es)
RU (1)	RU2241462C2 (es)
SI (1)	SI1307264T1 (es)
TW (1)	TWI275395B (es)
UY (1)	UY26860A1 (es)
WO (1)	WO2002009815A2 (es)
ZA (1)	ZA200300456B (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2240516T3 (es) *	2000-07-28	2005-10-16	F. Hoffmann-La Roche Ag	Nuevo uso de los inhibidores de lipasa.
AU2001289699B2 (en) *	2000-07-28	2006-06-01	Cheplapharm Arzneimittel Gmbh	New pharmaceutical composition
US7033373B2 (en)	2000-11-03	2006-04-25	Satiety, Inc.	Method and device for use in minimally invasive placement of space-occupying intragastric devices
US6558400B2 (en)	2001-05-30	2003-05-06	Satiety, Inc.	Obesity treatment tools and methods
US7083629B2 (en)	2001-05-30	2006-08-01	Satiety, Inc.	Overtube apparatus for insertion into a body
DE60330764D1 (de) *	2002-04-26	2010-02-11	Hoffmann La Roche	Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
US6746460B2 (en)	2002-08-07	2004-06-08	Satiety, Inc.	Intra-gastric fastening devices
US7214233B2 (en)	2002-08-30	2007-05-08	Satiety, Inc.	Methods and devices for maintaining a space occupying device in a relatively fixed location within a stomach
US7033384B2 (en)	2002-08-30	2006-04-25	Satiety, Inc.	Stented anchoring of gastric space-occupying devices
WO2004022076A1 (en) *	2002-09-09	2004-03-18	Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno	Branched alpha-glucans for weight management
US7220237B2 (en)	2002-10-23	2007-05-22	Satiety, Inc.	Method and device for use in endoscopic organ procedures
US7229428B2 (en)	2002-10-23	2007-06-12	Satiety, Inc.	Method and device for use in endoscopic organ procedures
US6656194B1 (en)	2002-11-05	2003-12-02	Satiety, Inc.	Magnetic anchoring devices
ES2528631T3 (es)	2003-04-08	2015-02-11	Progenics Pharmaceuticals, Inc.	Formulaciones farmacéuticas que contienen metilnaltrexona
US7175638B2 (en)	2003-04-16	2007-02-13	Satiety, Inc.	Method and devices for modifying the function of a body organ
US7097650B2 (en) *	2003-10-14	2006-08-29	Satiety, Inc.	System for tissue approximation and fixation
US7914543B2 (en)	2003-10-14	2011-03-29	Satiety, Inc.	Single fold device for tissue fixation
US8025794B2 (en) *	2003-12-19	2011-09-27	Shell Oil Company	Systems, methods, and catalysts for producing a crude product
US20050177176A1 (en)	2004-02-05	2005-08-11	Craig Gerbi	Single-fold system for tissue approximation and fixation
CA2556228C (en)	2004-02-13	2014-05-13	Satiety, Inc.	Methods for reducing hollow organ volume
WO2006004574A2 (en) *	2004-02-19	2006-01-12	Abbott Laboratories	Method for using gamma cyclodextrin to control blood glucose and insulin secretion
MXPA06009971A (es)	2004-02-27	2007-08-08	Satiety Inc	Metodos y dispositivo para reducir volumen de organo hueco.
US8628547B2 (en)	2004-03-09	2014-01-14	Ethicon Endo-Surgery, Inc.	Devices and methods for placement of partitions within a hollow body organ
US8449560B2 (en)	2004-03-09	2013-05-28	Satiety, Inc.	Devices and methods for placement of partitions within a hollow body organ
US8252009B2 (en)	2004-03-09	2012-08-28	Ethicon Endo-Surgery, Inc.	Devices and methods for placement of partitions within a hollow body organ
US9028511B2 (en)	2004-03-09	2015-05-12	Ethicon Endo-Surgery, Inc.	Devices and methods for placement of partitions within a hollow body organ
CA2561193A1 (en)	2004-03-26	2005-10-20	Satiety, Inc.	Systems and methods for treating obesity
US20050276781A1 (en) *	2004-06-09	2005-12-15	Ross Edward A	Molecularly imprinted phosphate binders for therapeutic use
WO2006035296A1 (en) *	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
US20060106288A1 (en)	2004-11-17	2006-05-18	Roth Alex T	Remote tissue retraction device
CN101171010B (zh) *	2005-03-07	2014-09-17	芝加哥大学	阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US9662325B2 (en)	2005-03-07	2017-05-30	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en)	2005-03-07	2013-09-03	The University Of Chicago	Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en)	2005-03-07	2013-08-27	The University Of Chicago	Use of opioid antagonists
AR057325A1 (es)	2005-05-25	2007-11-28	Progenics Pharm Inc	Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es)	2005-05-25	2007-11-14	Progenics Pharm Inc	SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
RU2283114C1 (ru) *	2005-06-07	2006-09-10	Открытое акционерное общество "Нижегородский химико-фармацевтический завод"	Композиция, обладающая гепатопротекторной активностью и нормализующая обменные процессы
PT1897558E (pt) *	2005-06-09	2013-11-06	Norgine Bv	Preparação sólida de 2-hexadeciloxi-6-metil-4h-3,1- benzoxazin-4-ona
WO2006134591A2 (en) *	2005-06-13	2006-12-21	Yeda Research And Development Co. Ltd.	Use of allylmercaptocaptopril for treating or preventing obesity and obesity related diseases
AR056499A1 (es) *	2005-09-06	2007-10-10	Serapis Farmaceuticals Ltd	Compuestos
US20090162314A1 (en) *	2005-11-08	2009-06-25	Huval Chad C	Magnesium-Containing Polymers for the Treatment of Hyperphosphatemia
US8067402B2 (en) *	2005-12-12	2011-11-29	Allaccem, Inc.	Methods and systems for coating an oral surface
EP1803714A1 (en) *	2005-12-27	2007-07-04	KRKA, tovarna zdravil, d.d., Novo mesto	Process for preparing crystalline forms of orlistat
US20100228037A1 (en) *	2006-01-25	2010-09-09	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Process for Preparing Allylmercaptocaptopril (Cpssa) and Related Asymmetrical Disulfides
CA2642255A1 (en) *	2006-02-14	2007-08-23	Teva Pharmaceutical Industries Ltd.	Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
ATE419838T1 (de) *	2006-02-14	2009-01-15	Teva Pharma	Pharmazeutische zubereitungsform von aliphatischen amin-polymeren und verfahren zu deren herstellung
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
US7964182B2 (en) *	2006-09-01	2011-06-21	USV, Ltd	Pharmaceutical compositions comprising phosphate-binding polymer
CA2661987C (en)	2006-09-01	2012-11-06	Usv Limited	Process for the preparation of sevelamer hydrochloride and formulation thereof
US7662373B2 (en) *	2006-09-18	2010-02-16	Thompson Ronald J	Method and composition of a medicament to decrease the adverse events of Olistat, an oral lipase inhibitor
US20080069906A1 (en) *	2006-09-18	2008-03-20	Thompson Ronald J	Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor
GB0618725D0 (en) *	2006-09-23	2006-11-01	Jagotec Ag	Composition containing inhibitors of gastro-intestinal lipase
WO2008070308A2 (en) *	2006-10-24	2008-06-12	Thompson Md Ronald J	Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, an oral lipase inhibitor, and a method with formulations to concurrently reduce fracture risk and insure appropriate fatsoluble vitamin supplementation when using orlistat, an oral lipase inhibitor, and a method o
EP2478895A3 (en) *	2006-12-22	2012-12-19	Ironwood Pharmaceuticals, Inc.	Compositions for treating esophageal disorders
EP1944025A1 (en) *	2007-01-09	2008-07-16	Ranbaxy Laboratories Limited	Stable pharmaceutical compositions of orlistat
WO2008103847A2 (en)	2007-02-21	2008-08-28	Allaccem, Incorporated	Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
PA8774201A1 (es)	2007-03-29	2009-06-23	Progenics Pharm Inc	Antagonista del receptor
MX2009010550A (es)	2007-03-29	2009-12-14	Progenics Pharm Inc	Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
PT2139890E (pt)	2007-03-29	2014-09-03	Wyeth Llc	Antagonistas do receptor opióide periférico e respectivas utilizações
US20090023682A1 (en) *	2007-07-19	2009-01-22	Joseph Artiss	Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8188068B2 (en) *	2007-08-10	2012-05-29	Allaccem, Inc.	Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153617B2 (en) *	2007-08-10	2012-04-10	Allaccem, Inc.	Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8153618B2 (en) *	2007-08-10	2012-04-10	Allaccem, Inc.	Bridged polycyclic compound based compositions for topical applications for pets
US20090074833A1 (en) *	2007-08-17	2009-03-19	Whiteford Jeffery A	Bridged polycyclic compound based compositions for controlling bone resorption
WO2009050720A1 (en) *	2007-10-15	2009-04-23	Inventis Dds Pvt Limited	Pharmaceutical composition of orlistat
CN101959892B (zh)	2008-02-06	2014-01-08	普罗热尼奇制药公司	(r),(r)-2,2’-二-甲基纳曲酮的制备和用途
PL216542B1 (pl) *	2008-03-20	2014-04-30	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8685995B2 (en)	2008-03-21	2014-04-01	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
US20100004218A1 (en) *	2008-06-20	2010-01-07	Whiteford Jeffery A	Bridged polycyclic compound based compositions for renal therapy
US20100016270A1 (en) *	2008-06-20	2010-01-21	Whiteford Jeffery A	Bridged polycyclic compound based compositions for controlling cholesterol levels
CA2735962A1 (en) *	2008-09-02	2010-04-15	Usv Limited	Crosslinked polymers
CA2676881C (en)	2008-09-30	2017-04-25	Wyeth	Peripheral opioid receptor antagonists and uses thereof
WO2010062861A2 (en)	2008-11-26	2010-06-03	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of obesity and diabetes
GB0900350D0 (en) *	2009-01-09	2009-02-11	Cambridge Entpr Ltd	Formulations of viable bacteria for oral delivery
EP2395987A1 (en)	2009-02-12	2011-12-21	Coöperatieve Mirzorg U.A., Arnhem	Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100330175A1 (en) *	2009-06-24	2010-12-30	Jobdevairakkam Christopher N	Cross-linked polyallylamine tablet core
US20110152204A1 (en) *	2009-12-18	2011-06-23	Satiogen Pharmaceuticals, Inc.	Treatment of Obesity or Diabetes with Bile Acid Sequestrants
ES2552657T3 (es)	2010-05-26	2015-12-01	Satiogen Pharmaceuticals, Inc.	Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
LT3400944T (lt)	2010-11-04	2020-09-25	Albireo Ab	Ibat inhibitoriai, skirt kepenų ligų gydymui
US11154559B2 (en)	2011-09-29	2021-10-26	Ethicon Endo-Surgery, Inc.	Methods and compositions of bile acids
SG11201401849QA (en)	2011-10-28	2014-05-29	Lumena Pharmaceuticals Inc	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SG10201406155QA (en)	2011-10-28	2014-11-27	Lumena Pharmaceuticals Inc	Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
EP2591768B1 (en) *	2011-11-14	2014-07-16	Deva Holding Anonim Sirketi	Single unit dosage formulations of sevelamer and fat soluble vitamins and surface active agents
JP2013147488A (ja) *	2011-12-21	2013-08-01	Taisho Pharmaceutical Co Ltd	固形製剤
GB201122213D0 (en) *	2011-12-23	2012-02-01	Norgine Bv	Compositions
US8252312B1 (en) *	2011-12-27	2012-08-28	David Wong	Oral solid composition comprising a lipid absorption inhibitor
PL2916852T3 (pl)	2012-11-06	2021-11-02	Sigrid Therapeutics Ab	Porowaty materiał z krzemionki do stosowania jako farmaceutyczny lub dietetyczny składnik czynny
TWI614017B (zh)	2012-12-21	2018-02-11	財團法人國家衛生研究院	包含中孔洞矽奈米粒子之組成物的用途
RU2552926C1 (ru) *	2014-06-23	2015-06-10	Общество с ограниченной ответственностью "ПРОМОМЕД"	Фармацевтическая комбинация для лечения и/или предупреждения нарушений, связанных с избыточным весом и/или ожирением, и способ лечения на ее основе
KR102560954B1 (ko)	2014-06-25	2023-07-31	이에이 파마 가부시키가이샤	고형 제제 및 그의 착색 방지 또는 착색 감소 방법
US10743813B2 (en)	2014-09-11	2020-08-18	Rattan Nath	Diabetes control using postprandial feedback
EP3012252A1 (en)	2014-10-24	2016-04-27	Ferring BV	Crystal modifications of elobixibat
CA3011595C (en) *	2016-02-09	2024-01-02	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
US10441604B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en)	2016-02-09	2019-10-15	Albireo Ab	Oral cholestyramine formulation and use thereof
US10786529B2 (en)	2016-02-09	2020-09-29	Albireo Ab	Oral cholestyramine formulation and use thereof
JP2020530448A (ja) *	2017-08-09	2020-10-22	アルビレオ・アクチボラグ	コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US11389545B2 (en) *	2018-01-09	2022-07-19	Aqua Regenerative Therapies Llc	Bioactive nanoparticles and methods for making same
US10793534B2 (en)	2018-06-05	2020-10-06	Albireo Ab	Benzothia(di)azepine compounds and their use as bile acid modulators
PE20210136A1 (es)	2018-06-20	2021-01-21	Albireo Ab	Formulacion farmaceutica de odevixibat
US11007142B2 (en)	2018-08-09	2021-05-18	Albireo Ab	Oral cholestyramine formulation and use thereof
US10722457B2 (en)	2018-08-09	2020-07-28	Albireo Ab	Oral cholestyramine formulation and use thereof
US11549878B2 (en)	2018-08-09	2023-01-10	Albireo Ab	In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN108685848B (zh) *	2018-08-13	2020-09-01	中山万汉制药有限公司	一种奥利司他口服乳剂及其制备方法
NL2022615B1 (en)	2019-02-21	2020-08-31	Patrick Alexander Unger	Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
CN111297826B (zh) *	2020-04-20	2021-08-03	鲁南制药集团股份有限公司	一种稳定的奥利司他胶囊及其制备方法
WO2025207711A1 (en) *	2024-03-27	2025-10-02	Mayo Foundation For Medical Education And Research	Lipase inhibitor compositions and methods for treating diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3692895A (en) *	1970-09-08	1972-09-19	Norman A Nelson	Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
IT1052819B (it) *	1975-12-12	1981-07-20	Fargal Pharmasint Lab Biochim	Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
CA1247547A (en)	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
DE3414609C1 (de) *	1984-04-18	1985-06-20	Daimler-Benz Ag, 7000 Stuttgart	Vorrichtung zur Beeinflussung eines Kuehlluftstromes
US4632925A (en) *	1985-10-07	1986-12-30	Hoffmann-La Roche Inc.	N-substituted diphenylpiperidines and antiobesity use thereof
IT1190349B (it) *	1986-06-16	1988-02-16	Prodotti Formenti Srl	Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
SU1697823A1 (ru) *	1988-08-01	1991-12-15	Киевский государственный институт усовершенствования врачей	Способ лечени алиментарно-конституционального ожирени
US5063210A (en) *	1989-04-20	1991-11-05	Lange Iii Louis G	Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5344453A (en) *	1991-05-30	1994-09-06	Boston Medical Products, Inc.	Thyroplasty implant
US5616570A (en) *	1991-10-18	1997-04-01	Lange, Iii; Louis G.	Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) *	1992-06-24	2006-12-19	Dorothea Isler	Foodstuffs and feedstuffs containing a lipase inhibitor
US5607669A (en) *	1994-06-10	1997-03-04	Geltex Pharmaceuticals, Inc.	Amine polymer sequestrant and method of cholesterol depletion
TW381025B (en) *	1993-08-05	2000-02-01	Hoffmann La Roche	Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US5667775A (en) *	1993-08-11	1997-09-16	Geltex Pharmaceuticals, Inc.	Phosphate-binding polymers for oral administration
US5569452A (en) *	1993-08-31	1996-10-29	Tsrl, Inc.	Pharmaceutical formulation having enhanced bile acid binding affinity
TW474813B (en) *	1994-06-10	2002-02-01	Geltex Pharma Inc	Alkylated composition for removing bile salts from a patient
US5545414A (en) *	1995-03-22	1996-08-13	Abbott Laboratories	Cholesterol lowering food product
JP3832871B2 (ja) *	1995-04-03	2006-10-11	日本製粉株式会社	リパーゼ阻害剤
KR19980702533A (ko)	1995-12-26	1998-07-15	도리이 신이찌로	프로시아니딘을 유효성분으로 하는 항비만제
US5612026A (en) *	1996-01-25	1997-03-18	The Procter & Gamble Company	Cholesterol lowering drink mix compositons
US5883109A (en)	1996-07-24	1999-03-16	Bristol-Myers Squibb Company	Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en)	1997-01-17	2000-05-23	Bristol-Myers Squibb Co.	Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US6004996A (en)	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
JP3807464B2 (ja)	1997-11-17	2006-08-09	康二嘉島	肥満防止剤
GB9727131D0 (en)	1997-12-24	1998-02-25	Knoll Ag	Therapeutic agents
US6267952B1 (en)	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
ES2200493T3 (es)	1998-01-09	2004-03-01	Genzyme Corporation	Composicion de polimeros e inhibidores de lipasa enlazantes de grasa para el tratamiento de obesidad.
FI113356B (fi)	1998-05-20	2004-04-15	Upm Kymmene Corp	Pakkauksenmuodostuslaite
DE69916288T2 (de) *	1998-08-14	2005-03-24	F. Hoffmann-La Roche Ag	Lipasehemmer und chitosan enthaltende arzneimittel
ATE293970T1 (de) *	1998-08-14	2005-05-15	Hoffmann La Roche	Lipasehemmer enthaltende pharmazeutische zusammensetzungen
US6607749B1 (en)	1998-09-08	2003-08-19	Smithkline Beecham Corporation	Lipstatin derivative-soluble fiber tablets
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
AU2542500A (en)	1999-01-22	2000-08-07	Hunza Di Maria Carmela Marazzita S.A.S.	Lipoprotein complexes and compositions containing them
AR025587A1 (es)	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) *	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones lipidas solidas
AU2001289699B2 (en) *	2000-07-28	2006-06-01	Cheplapharm Arzneimittel Gmbh	New pharmaceutical composition

2001
- 2001-07-19 AU AU2001289699A patent/AU2001289699B2/en not_active Expired
- 2001-07-19 PL PL366105A patent/PL204443B1/pl unknown
- 2001-07-19 CA CA002416901A patent/CA2416901C/en not_active Expired - Lifetime
- 2001-07-19 RS YUP-50/03A patent/RS50397B/sr unknown
- 2001-07-19 JP JP2002515366A patent/JP4265911B2/ja not_active Expired - Lifetime
- 2001-07-19 SI SI200130249T patent/SI1307264T1/xx unknown
- 2001-07-19 DE DE60106623T patent/DE60106623T2/de not_active Expired - Lifetime
- 2001-07-19 NZ NZ523684A patent/NZ523684A/en not_active IP Right Cessation
- 2001-07-19 IL IL15400801A patent/IL154008A0/xx unknown
- 2001-07-19 MX MXPA03000771A patent/MXPA03000771A/es active IP Right Grant
- 2001-07-19 EP EP01969439A patent/EP1307264B1/en not_active Expired - Lifetime
- 2001-07-19 PT PT01969439T patent/PT1307264E/pt unknown
- 2001-07-19 HU HU0301281A patent/HU229292B1/hu unknown
- 2001-07-19 KR KR1020037001277A patent/KR100572785B1/ko not_active Expired - Fee Related
- 2001-07-19 RU RU2003104801/15A patent/RU2241462C2/ru active
- 2001-07-19 ES ES01969439T patent/ES2230362T3/es not_active Expired - Lifetime
- 2001-07-19 WO PCT/EP2001/008363 patent/WO2002009815A2/en not_active Ceased
- 2001-07-19 AT AT01969439T patent/ATE279961T1/de active
- 2001-07-19 ME MEP-905/08A patent/MEP90508A/xx unknown
- 2001-07-19 AU AU8969901A patent/AU8969901A/xx active Pending
- 2001-07-19 BR BRPI0112799A patent/BR0112799B1/pt not_active IP Right Cessation
- 2001-07-19 CZ CZ20030582A patent/CZ302087B6/cs not_active IP Right Cessation
- 2001-07-19 HR HR20030029A patent/HRP20030029B1/xx not_active IP Right Cessation
- 2001-07-19 CN CNB018135196A patent/CN100423715C/zh not_active Expired - Lifetime
- 2001-07-24 PE PE2001000743A patent/PE20020336A1/es active IP Right Grant
- 2001-07-24 JO JO2001125A patent/JO2320B1/en active
- 2001-07-25 US US09/912,957 patent/US6756364B2/en not_active Expired - Lifetime
- 2001-07-26 PA PA20018523201A patent/PA8523201A1/es unknown
- 2001-07-26 MY MYPI20013543 patent/MY127247A/en unknown
- 2001-07-26 AR ARP010103574A patent/AR033548A1/es not_active Application Discontinuation
- 2001-07-27 UY UY26860A patent/UY26860A1/es not_active Application Discontinuation
- 2001-07-27 GT GT200100152A patent/GT200100152A/es unknown
- 2001-07-28 EG EG20010821A patent/EG24357A/xx active
- 2001-09-04 TW TWNEWPHARMA patent/TWI275395B/zh not_active IP Right Cessation
2003
- 2003-01-16 IL IL154008A patent/IL154008A/en active IP Right Grant
- 2003-01-16 ZA ZA200300456A patent/ZA200300456B/en unknown
- 2003-01-24 EC EC2003004450A patent/ECSP034450A/es unknown
- 2003-01-27 MA MA27015A patent/MA26937A1/fr unknown
- 2003-01-27 NO NO20030418A patent/NO330546B1/no not_active IP Right Cessation
- 2003-11-20 US US10/718,049 patent/US20040105838A1/en not_active Abandoned
2005
- 2005-02-18 US US11/062,086 patent/US20050136030A1/en not_active Abandoned
2006
- 2006-08-07 US US11/499,955 patent/US20060269510A1/en not_active Abandoned
2008
- 2008-09-09 JP JP2008230880A patent/JP2009073833A/ja active Pending
2010
- 2010-04-20 US US12/763,794 patent/US8071571B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CZ302087B6 (cs)	2010-10-06
NZ523684A (en)	2005-04-29
HUP0301281A3 (en)	2005-05-30
JP2009073833A (ja)	2009-04-09
ZA200300456B (en)	2004-04-16
NO20030418D0 (no)	2003-01-27
US20020035089A1 (en)	2002-03-21
PT1307264E (pt)	2005-02-28
EP1307264B1 (en)	2004-10-20
HRP20030029B1 (en)	2005-06-30
NO330546B1 (no)	2011-05-16
DE60106623D1 (de)	2004-11-25
ME00671B (me)	2011-12-20
CA2416901A1 (en)	2002-02-07
WO2002009815A3 (en)	2002-04-18
ECSP034450A (es)	2003-03-10
JP2004505067A (ja)	2004-02-19
HRP20030029A2 (en)	2004-02-29
RS50397B (sr)	2009-12-31
NO20030418L (no)	2003-01-27
BR0112799A (pt)	2003-07-01
EG24357A (en)	2009-03-04
CA2416901C (en)	2007-07-03
US20050136030A1 (en)	2005-06-23
AU8969901A (en)	2002-02-13
PL204443B1 (pl)	2010-01-29
SI1307264T1 (en)	2005-02-28
MY127247A (en)	2006-11-30
US20060269510A1 (en)	2006-11-30
US20100203032A1 (en)	2010-08-12
JP4265911B2 (ja)	2009-05-20
PL366105A1 (en)	2005-01-24
ATE279961T1 (de)	2004-11-15
AU2001289699B2 (en)	2006-06-01
PA8523201A1 (es)	2002-10-24
EP1307264A2 (en)	2003-05-07
BR0112799B1 (pt)	2017-10-24
GT200100152A (es)	2002-05-16
IL154008A0 (en)	2003-07-31
YU5003A (sh)	2006-01-16
US6756364B2 (en)	2004-06-29
ES2230362T3 (es)	2005-05-01
US8071571B2 (en)	2011-12-06
KR100572785B1 (ko)	2006-04-19
HUP0301281A2 (hu)	2003-08-28
KR20030029796A (ko)	2003-04-16
HK1058636A1 (zh)	2004-05-28
CN1444495A (zh)	2003-09-24
AR033548A1 (es)	2003-12-26
DE60106623T2 (de)	2006-02-02
CN100423715C (zh)	2008-10-08
MXPA03000771A (es)	2003-06-04
TWI275395B (en)	2007-03-11
US20040105838A1 (en)	2004-06-03
MA26937A1 (fr)	2004-12-20
IL154008A (en)	2011-12-29
CZ2003582A3 (cs)	2004-02-18
WO2002009815A2 (en)	2002-02-07
RU2241462C2 (ru)	2004-12-10
HU229292B1 (en)	2013-10-28
JO2320B1 (en)	2005-09-12
UY26860A1 (es)	2002-01-31
PE20020336A1 (es)	2002-05-08

Publication	Publication Date	Title
MEP90508A (en)	2011-12-20	New pharmaceutical composition
EA200501805A1 (ru)	2006-06-30	Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
BG66084B1 (bg)	2011-03-31	Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE294158T1 (de)	2005-05-15	Ein monoether von probucol und methoden zur hemmung der vcam-1 expression
WO2001062280A3 (en)	2002-01-31	Lipase-containing composition and methods of use thereof
TR200000927T2 (tr)	2000-11-21	Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
ATE451369T1 (de)	2009-12-15	Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
NO20030845D0 (no)	2003-02-24	Utvalgte fusjonerte pyrrolokarbazoler
ATE416761T1 (de)	2008-12-15	Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
DE69905476D1 (en)	2003-03-27	Phosphonsaürederivate als ptp-1b-inhibitoren
DE60013098D1 (de)	2004-09-23	Zusammensetzung zur hautdesinfizierung
WO2003072593A3 (en)	2004-09-30	Bone targeting peptides
BRPI0517435A (pt)	2008-10-07	triazóis úteis como inibidores de proteìna cinase
DE60141636D1 (de)	2010-05-06	Phospholipidderivate von valproinsäure und ihre kombinationen
DE60327811D1 (de)	2009-07-09	Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
AR039664A1 (es)	2005-03-02	Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
BR0008382A (pt)	2002-02-05	Formulação de liberação controlada para tratamento de copd
BR0210493A (pt)	2004-06-22	Composição, e, método para remover cerume humano
IL144199A0 (en)	2002-05-23	Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TR200200494T2 (tr)	2003-02-21	Yağlı asit sintazı inhibitörleri.
DE60142786D1 (de)	2010-09-23	Zusammensetzungen und methoden zur behandlung von candidosen
PT1268463E (pt)	2005-05-31	4-pironas substituidas com arilo e heteroarilo policiclicos uteis para a inibicao selectiva da cascata de coagulacao
ATE333887T1 (de)	2006-08-15	Verfahren zur behandlung von instabiler angina pectoris
ATE319689T1 (de)	2006-03-15	Naphthamidin-urokinasinhibitoren
DK1144348T3 (da)	2006-06-12	LTA4-hydrolaseinhibitorer